Hepatitis Monthly

Published by: Kowsar

The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis

Marwa Khairy 1 , Rabab Fouad 1 , Mahassen Mabrouk 1 , Wafaa El-Akel 1 , Abu Bakr Awad 2 , Rabab Salama 1 , * , Mayada Elnegouly 1 and Olfat Shaker 3
Authors Information
1 Endemic Medicine Department and Hepatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt
2 Bioinformatic and Statistic Department, Faculty of Computer Sciences, Cairo University, Cairo, Egypt
3 Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Cairo University, Cairo, Egypt
Article information
  • Hepatitis Monthly: July 01, 2013, 13 (7); e10509
  • Published Online: July 17, 2013
  • Article Type: Research Article
  • Received: January 31, 2013
  • Revised: April 10, 2013
  • Accepted: May 25, 2013
  • DOI: 10.5812/hepatmon.10509

To Cite: Khairy M, Fouad R, Mabrouk M, El-Akel W, Bakr Awad A, et al. The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis, Hepat Mon. 2013 ; 13(7):e10509. doi: 10.5812/hepatmon.10509.

Copyright © 2013, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Lavanchy D. The global burden of hepatitis C. Liver Int. 2009; 29 Suppl 1: 74-81[DOI][PubMed]
  • 2. El-Raziky MS, El-Hawary M, Esmat G, Abouzied AM, El-Koofy N, Mohsen N, et al. Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children. World J Gastroenterol. 2007; 13(12): 1828-32[PubMed]
  • 3. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout egypt. J Infect Dis. 2000; 182(3): 698-707[DOI][PubMed]
  • 4. Lyra AC, Ramrakhiani S, Bacon BR, Di Bisceglie AM. Infection with hepatitis C virus genotype 4 in the United States. J Clin Gastroenterol. 2004; 38(1): 68-71[PubMed]
  • 5. Payan C, Roudot-Thoraval F, Marcellin P, Bled N, Duverlie G, Fouchard-Hubert I, et al. Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat. 2005; 12(4): 405-13[DOI][PubMed]
  • 6. van Asten L, Verhaest I, Lamzira S, Hernandez-Aguado I, Zangerle R, Boufassa F, et al. Spread of hepatitis C virus among European injection drug users infected with HIV: a phylogenetic analysis. J Infect Dis. 2004; 189(2): 292-302[DOI][PubMed]
  • 7. El-Zayadi AR, Attia M, Barakat EM, Badran HM, Hamdy H, El-Tawil A, et al. Response of hepatitis C genotype-4 naive patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study. Am J Gastroenterol. 2005; 100(11): 2447-52[DOI][PubMed]
  • 8. Kamal SM. Hepatitis C virus genotype 4 therapy: progress and challenges. Liver Int. 2011; 31 Suppl 1: 45-52[DOI][PubMed]
  • 9. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, et al. Hepatitis C: viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int. 2010; 30(9): 1259-69[DOI][PubMed]
  • 10. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009; 461(7262): 399-401[DOI][PubMed]
  • 11. Huang CF, Huang JF, Yang JF, Hsieh MY, Lin ZY, Chen SC, et al. Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin. J Hepatol. 2012; 56(1): 34-40[DOI][PubMed]
  • 12. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010; 138(4): 1338-45, 45 e1-7[DOI][PubMed]
  • 13. Khattab MA, Ferenci P, Hadziyannis SJ, Colombo M, Manns MP, Almasio PL, et al. Management of hepatitis C virus genotype 4: recommendations of an international expert panel. J Hepatol. 2011; 54(6): 1250-62[DOI][PubMed]
  • 14. Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte W, Nischalke HD, et al. Interferon-lambda serum levels in hepatitis C. J Hepatol. 2011; 54(5): 859-65[DOI][PubMed]
  • 15. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Yasui Y, et al. A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. Hepatol Res. 2010; 40(4): 251-60[DOI][PubMed]
  • 16. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al. Pretreatment prediction of response to peginterferon plus ribavirin therapy in genotype 1 chronic hepatitis C using data mining analysis. J Gastroenterol. 2011; 46(3): 401-9[DOI][PubMed]
  • 17. Izumi N, Asahina Y, Kurosaki M. Predictors of virological response to a combination therapy with pegylated interferon plus ribavirin including virus and host factors. Hepat Res Treat. 2010; 2010: 703602[DOI][PubMed]
  • 18. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24(2): 289-93[DOI][PubMed]
  • 19. Olshen L, Breiman JH, Friedman RA, Stone Charles J. Classification and Regression Trees. 1984;
  • 20. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002; 36(5 Suppl 1)-9[DOI][PubMed]
  • 21. Esmat G, Abouzied A, Mohamed MK, et al. Treatment with Peg Interferon alpha 2-b (PEC INF) plus ribavirin compared to Interferon alpha-2b (INF alfa-2b) plus Ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4. Hepatol Res. 2002; 36(4)
  • 22. Hasan F, Asker H, Al-Khaldi J, Siddique I, Al-Ajmi M, Owaid S, et al. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4. Am J Gastroenterol. 2004; 99(9): 1733-7[DOI][PubMed]
  • 23. Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut. 2009; 58(12): 1662-9[DOI][PubMed]
  • 24. Kamal SM, El Kamary SS, Shardell MD, Hashem M, Ahmed IN, Muhammadi M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology. 2007; 46(6): 1732-40[DOI][PubMed]
  • 25. Gad RR, Males S, El Makhzangy H, Shouman S, Hasan A, Attala M, et al. Predictors of a sustained virological response in patients with genotype 4 chronic hepatitis C. Liver Int. 2008; 28(8): 1112-9[DOI][PubMed]
  • 26. Asselah T, De Muynck S, Broet P, Masliah-Planchon J, Blanluet M, Bieche I, et al. IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. J Hepatol. 2012; 56(3): 527-32[DOI][PubMed]
  • 27. De Nicola S, Aghemo A, Rumi MG, Galmozzi E, Valenti L, Soffredini R, et al. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4. Hepatology. 2012; 55(2): 336-42[DOI][PubMed]
  • 28. Al Ashgar H, Helmy A, Khan MQ, Al Kahtani K, Al Quaiz M, Rezeig M, et al. Predictors of sustained virological response to a 48-week course of pegylated interferon alfa-2a and ribavirin in patients infected with hepatitis C virus genotype 4. Ann Saudi Med. 2009; 29(1): 4-14[PubMed]
  • 29. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem. 2009; 284(31): 20869-75[DOI][PubMed]
  • 30. Males S, Gad RR, Esmat G, Abobakr H, Anwar M, Rekacewicz C, et al. Serum alpha-foetoprotein level predicts treatment outcome in chronic hepatitis C. Antivir Ther. 2007; 12(5): 797-803[PubMed]
  • 31. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b. J Med Virol. 2007; 79(11): 1686-95[DOI][PubMed]
  • 32. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, et al. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol. 2007; 22(5): 669-75[DOI][PubMed]
  • 33. Abdoul H, Mallet V, Pol S, Fontanet A. Serum alpha-fetoprotein predicts treatment outcome in chronic hepatitis C patients regardless of HCV genotype. PLoS One. 2008; 3(6)[DOI][PubMed]
  • 34. Khairy M, Abdel-Rahman M, El-Raziky M, El-Akel W, Zayed N, Khatab H, et al. Non-invasive prediction of hepatic fibrosis in patients with chronic HCV based on the routine pre-treatment workup. Hepat Mon. 2012; 12(11)[DOI][PubMed]
  • 35. Shiratori Y, Omata M. Predictors of the efficacy of interferon therapy for patients with chronic hepatitis C before and during therapy: how does this modify the treatment course? J Gastroenterol Hepatol. 2000; 15 Suppl-51[PubMed]
  • 36. Ciesla A, Bociaga-Jasik M, Sobczyk-Krupiarz I, Glowacki MK, Owczarek D, Cibor D, et al. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C. World J Gastroenterol. 2012; 18(35): 4892-7[DOI][PubMed]
  • 37. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798-801[DOI][PubMed]
  • 38. El-Awady MK, Mostafa L, Tabll AA, Abdelhafez TH, Bader El Din NG, Zayed N, et al. Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease. Hepat Mon. 2012; 12(4): 271-7[DOI][PubMed]
  • 39. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010; 138(7): 2307-14[DOI][PubMed]
  • 40. Marabita F, Aghemo A, De Nicola S, Rumi MG, Cheroni C, Scavelli R, et al. Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection. Hepatology. 2011; 54(4): 1127-34[DOI][PubMed]
  • 41. Fabris C, Falleti E, Cussigh A, Bitetto D, Fontanini E, Bignulin S, et al. IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: role in the course of chronic viral hepatitis and the development of HCC. J Hepatol. 2011; 54(4): 716-22[DOI][PubMed]
  • 42. Kamal SM, Nasser IA. Hepatitis C genotype 4: What we know and what we don't yet know. Hepatology. 2008; 47(4): 1371-83[DOI][PubMed]
  • 43. Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, et al. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol. 2011; 83(3): 445-52[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments